![](/wp-content/uploads/2018/10/flyZmjEzSJqf9Cv9bkVk.png)
$599
New Semaglutide Retinopathy Study Called FOCUS
A new study evaluating the effect of semaglutide on retinopathy in T2DM, called “FOCUS,” has been posted on CT.gov. Recall, data from Novo’s SUSTAIN 6 study showed an imbalance in retinopathy with a 1.76 hazard ratio (50 events with sema vs. 29 with placebo) which resulted in a label warning. Below, FENIX provides details from the study as well as thoughts on how Novo will leverage the data.